¼¼°èÀÇ °­¾ÐÁ¦ ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)
Antihypertensive Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1665183
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 140 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è °­¾ÐÁ¦ ½ÃÀåÀº 2024³â¿¡ 239¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç 2025³âºÎÅÍ 2034³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 4.1%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

ÀÌ ¼ºÀåÀº ¼¼°è °íÇ÷¾ÐÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. °íÇ÷¾ÐÀº ¹«Áõ»óÀÌ¸ç ½É°¢ÇÑ °Ç°­ À§ÇèÀÌ Àֱ⠶§¹®¿¡ Á¾Á¾ "ħ¹¬ÀÇ »ìÀÎÀÚ"¶ó°íÇÕ´Ï´Ù.

Antihypertensive Drugs Market-IMG1

Àα¸ÀÇ °í·ÉÈ­¿Í ½Ä»ýȰÀÇ È¥¶õ, ½ºÆ®·¹½º, ¿îµ¿ ºÎÁ· µî »ýȰ ½À°üÀÇ ¾ÇÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó °íÇ÷¾Ð·üÀº °è¼Ó »ó½ÂÇϰí È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¾à¹° Á¦ÇüÀÇ ²÷ÀÓ¾ø´Â Áøº¸´Â ¿ø°Ý ¸ð´ÏÅ͸µ ¹× °³º°È­µÈ Åõ¾à °èȹ°ú °°Àº µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕ°ú ÇÔ²² Ä¡·á dz°æÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÉÀ庴°ú ³úÁ¹Áß°ú °°Àº ÅëÁ¦µÇÁö ¾ÊÀº °íÇ÷¾Ð°ú °ü·ÃµÈ ÇÕº´Áõ¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â Áø´Ü°ú Àû±ØÀûÀÎ Ä¡·áÀÇ µµÀÔÀ» ÃËÁøÇϰí Ç÷¾Ð ¾ïÁ¦Á¦ÀÇ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ È®º¸Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 239¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 355¾ï ´Þ·¯
CAGR 4.1%

½ÃÀåÀº Ä¡·á À¯Çüº°·Î ÀÌ´¢Á¦, ACE ¾ïÁ¦Á¦, ¾ÈÁö¿ÀÅٽмö¿ëü Â÷´ÜÁ¦, º£Å¸ Â÷´ÜÁ¦, Ä®½· ä³Î Â÷´ÜÁ¦, ·¹´Ñ ¾ïÁ¦Á¦, ¾ËÆÄ Â÷´ÜÁ¦, Ç÷°ü È®ÀåÁ¦ ¹× ±âŸ Ä¡·á¹ýÀ¸·Î ºÐ·ùµË´Ï´Ù. 2024³â¿¡´Â Ç÷¾ÐÀ» ³·Ãß´Â È¿°ú°¡ ÀÎÁ¤µÈ Ƽ¾ÆÁöµå°è ÀÌ´¢Á¦°¡ ³Î¸® »ç¿ëµÇ¾î ÀÌ´¢Á¦ ºÎ¹®ÀÌ 22.4%·Î ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â ·çÇÁ ÀÌ´¢Á¦¿Í Ä®·ý º¸Àü ÀÌ´¢Á¦µµ Æ÷ÇÔµÇ¾î ´Ù¾çÇÑ Ä¡·á ¿ä±¸¸¦ ÃæÁ·ÇÕ´Ï´Ù. ¶Ç ´Ù¸¥ ÁÖ¿ä Ä«Å×°í¸®ÀÎ º£Å¸ Â÷´ÜÁ¦´Â º£Å¸ 1 ¼±Åüº°ú ³»Àμº ±³°¨ ½Å°æ ÀڱؼºÀ¸·Î ±¸ºÐµÇ¸ç °³º° ȯÀÚÀÇ ¿ä±¸¿¡ µû¶ó °³º°È­ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

¾à À¯Çüº°·Î º¸¸é, ½ÃÀåÀº 1Â÷¼º °íÇ÷¾Ð Ä¡·áÁ¦¿Í 2Â÷¼º °íÇ÷¾Ð Ä¡·áÁ¦·Î ³ª´¹´Ï´Ù. 1Â÷¼º °íÇ÷¾Ð Ä¡·á´Â ÀÌ Áúº´ÀÇ ³ôÀº À¯º´·üÀ» ¹Ý¿µÇÏ¿© 2024³â ½ÃÀå Á¡À¯À²¿¡¼­ 90.8%¸¦ Â÷ÁöÇß½À´Ï´Ù. 1Â÷¼º °íÇ÷¾ÐÀº ¶óÀÌÇÁ½ºÅ¸Àϰú À¯ÀüÀû ¿äÀΰú °ü·ÃÀÌ ¸¹À¸¸ç È¿°úÀûÀ̰í Àå±âÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹Àº °­¾ÐÁ¦ ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ ÁöÀ§¸¦ À¯ÁöÇϰí ÀÖÀ¸¸ç, 2024³â¿¡´Â 90¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. ÀÌ ¸®´õ½ÊÀº ³ôÀº Ç÷¾Ð ÀÌȯÀ², °ß°íÇÑ °Ç°­ °ü¸® ÀÎÇÁ¶ó ¹× R&D¿¡ ´ëÇÑ ¸¹Àº ÅõÀÚ·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ¸·Î ȯÀÚ´Â ÃÖ÷´Ü ¾à¹°À» »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¶±âÁø´Ü Ä·ÆäÀΰú ÷´Ü Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ÁÖ·ÂÇÔÀ¸·Î½á ±¹°¡ ÀüüÀÇ º¸±Þ·üµµ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ã߰衤¿¹Ãø : Ä¡·á¹ýº°, 2021-2034³â

Á¦6Àå ½ÃÀå Ã߰衤¿¹Ãø : ¾àÁ¦ À¯Çüº°, 2021-2034³â

Á¦7Àå ½ÃÀå Ã߰衤¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2034³â

Á¦8Àå ½ÃÀå Ã߰衤¿¹Ãø : À¯Åë ä³Îº°, 2021-2034³â

Á¦9Àå ½ÃÀå Ã߰衤¿¹Ãø : Áö¿ªº°, 2021-2034³â

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Antihypertensive Drugs Market, valued at USD 23.9 billion in 2024, is set to expand at a compound annual growth rate (CAGR) of 4.1% from 2025 to 2034. This growth is largely driven by the increasing prevalence of hypertension worldwide, a condition often referred to as the "silent killer" due to its asymptomatic nature and severe health risks.

Antihypertensive Drugs Market - IMG1

As populations age and lifestyle factors such as poor diet, stress, and lack of exercise persist, hypertension rates continue to rise, fueling the demand for effective treatments. Continuous advancements in drug formulations, coupled with the integration of digital health technologies like remote monitoring and personalized medication plans, are reshaping treatment landscapes. Furthermore, heightened awareness of the complications associated with unmanaged hypertension, such as heart disease and stroke, is encouraging early diagnosis and proactive treatment adoption, ensuring a sustained demand for antihypertensive drugs.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$23.9 Billion
Forecast Value$35.5 Billion
CAGR4.1%

The market is categorized by therapy type into diuretics, ACE inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, renin inhibitors, alpha-blockers, vasodilators, and other treatments. In 2024, the diuretics segment commanded the largest share at 22.4%, thanks to the widespread use of thiazide diuretics, which are recognized for their effectiveness in reducing blood pressure. This segment also includes loop and potassium-sparing diuretics, catering to diverse treatment requirements. Beta blockers, another key category, are further segmented into beta-1 selective and intrinsic sympathomimetic variants, offering personalized solutions based on individual patient needs.

By drug type, the market divides into treatments for primary and secondary hypertension. Primary hypertension treatments dominated with a commanding 90.8% market share in 2024, reflecting the high global prevalence of this condition. Primary hypertension, often linked to lifestyle and genetic factors, underscores the growing need for effective, long-term treatment options.

The United States remains a dominant player in the antihypertensive drugs market, generating USD 9 billion in revenue in 2024. This leadership is attributed to the high incidence of hypertension, coupled with robust healthcare infrastructure and significant investment in research and development. Regulatory approvals for innovative therapies are enabling patients to access cutting-edge medications, further driving market growth. The focus on early diagnosis campaigns and advanced treatment protocols is also accelerating adoption rates across the country.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 – 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â